LY-3493269
- Generic Name
- LY-3493269
A Multiple-Dose Study of LY3493269 in Healthy Participants
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT05794243
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of LY3493269 in Healthy Participants
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT04682106
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of LY3493269 in Participants With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT04515576
- Locations
- 🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Safety Study of LY3493269 in Healthy Participants
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT04498390
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath